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S232 Oral Presentationsinitial loss of donor chimerism had a 31% response rate. No re-
sponses were seen in four patients who received their first DLI .
100 days after loss of donor chimerism. Three patients had insuffi-
cient data to determine timing of decrease in donor chimerism.
Conclusions: Prompt initiation of DLI for mixed chimerism in-
creases the likelihood of improvement in donor chimerism.
Table 1. T Cell Donor Lymphocyte Infusion for Mixed Donor
Chimerism: Characteristics for Responders Compared to
Non-responders
Responders Non-respondersTable.
Patient/Dgn Donor(Match) A
1 / HLH URD (7/8)
2 / XLP MSD (8/8)
3 / XLP URD (7/8)
4 / FA MUD (8/8)
5 / CML MUD (8/8)
HLH: hemophagocytic lymphohist
URD: unrelated donor; MSD: mat
megalovirus; EBV: Epstein-Barr vir(N 5 16)ge (y)
0.6 Blo
1.8 Blo
N
1.8 Blo
5.8 Blo
10.4 Blo
iocytosis; XL
ched sibling d
us, adeno: a(N 5 17)Infections
od-CMV; NS-none
od-adeno;
S-metapneumovir
od-none; NS-none
od-none; BAL-non
od-BK; BAL-EBV
P: X-linked lymp
onor; MUD: mat
denovirus; BK-BKp valueMean # of T cell doses 2.8 ± 3.1 3.6 ± 2.0 0.36
Mean first T cell dose (X 106) 2.4 ± 4.8 2.8 ± 3.4 0.56
Mean total T cell dose (X 107) 5.7 ± 11.1 5.9 ± 10.2 0.95
Days post transplant for first DLI 86 ± 41 143 ± 48 0.0007
Days post transplant for initial
chimerism drop of at least 10%41 ± 26 72 ± 65 0.09Days between chimerism
drop and first DLI42 ± 27 82 ± 51 0.008Last engraftment prior to first DLI 39 ± 22 45± 16 0.4
Acute GVHD following DLI 10 (62.5%) 080
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TIENTS WITH HEREDITARY BONE MARROW FAILURE SYNDROMES
WITHOUT TOTAL BODY IRRADIATION
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Background: Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) remains as the treatment of choice to correct the hema-
tological abnormalities in patients with Fanconi anemia (FA) andDi-
amond-Blackfan anemia (DBA). The aim of this study is to analyze
the outcomes of allo-HSCT on FA and DBA at our center.
Methods: We prospectively analyzed the outcomes of 33 patients
with FA and 7 patients with DBA (25 male and 15 female) who
had undergone allo-HSCT between January 2008 and September
2011 in our institution. The median age at transplantation was 8
years (age range, 1-14 years). Conditioning regimen consisted of bu-
sulfan (0.2 mg/kg/day for 4 consecutive days in divided doses) plus
cyclophosphamide (15mg/kg/day intravenously for 4 days) in FA pa-
tients and busulfan (4 mg/kg/day for 4 consecutive days in divided
doses) plus cyclophosphamide (50 mg/kg/day intravenously for 4
days) in DBA patients. Twenty patients received horse antithymo-
cyte globulin (10 mg/kg intravenously). No radiation therapy was
given. Thirty four patients received transplants fromHLA-matched
donors (23 from sibling and 11 from other related donors), five pa-
tients received transplants from one-antigen locus mismatched do-
nors and one patient received cord blood stem cell from partially
matched unrelated donor. Cyclosporine and methotrexate were
used as Graft-versus-host disease (GVHD) prophylaxis.
Results: The median time to neutrophil engraftment was 11 days
(range, 8-28 days) and the median time to platelet engraftment was
19 days (range, 9-61 days). The 6-month survival rate was 88.5%Days fro
to
us
e
hoproliferative
ched unrelate
virus; echo: e(SE 5 6.3%) for FA patients and 75% (SE 5 21.7%) for DBA pa-
tients. Thirty one patients developed acute GVHD (23, grade I-II
and 8, grade III-IV). Three deaths and one rejection occurred among
FA patients and one DBA patient died at a median follow-up of 6
months (range 1-41months). The causes of deaths were failure of en-
graftment, renal failure and sepsis in FA and acute GVHD grade IV
in DBA.
Conclusion: Despite the high incidence of aGVHD in our study,
overall survival in our study was comparable with other studies advo-
cating fludarabine-based regimen in hereditary bone marrow failure
syndromes. Therefore, we propose to conduct a multicenter, pro-
spective study to evaluate the outcome of regimens employed in he-
reditary bone marrow failure syndromes.
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PULMONARY HYPERTENSION (PH) IN PATIENTS WITH HEMATOPOIETIC
STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOP-
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Grimley, M.S.1, Davies, S.M.1 1Cincinnati Children’s Hospital Medical
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Pulmonary hypertension is rarely included in the differential diag-
nosis of respiratory failure following pediatric hematopoietic stem
cell transplant (HSCT) as the clinical presentation is non-specific
and may mimic other causes of respiratory failure. Hence, this diag-
nosis requires a high degree of suspicion.Moreover, the etiology and
pathogenesis of PH in HSCT are poorly understood.We describe 5
allogeneic HSCT patients that had TMA and developed hypoxemic
respiratory failure with evidence of PH. All 5 patients had active
signs of TMA (microangiopathic anemia, hypertension, proteinuria)
when presented with hypoxemia that progressed to respiratory fail-
ure requiring mechanical ventilation. Notably, at presentation there
was no significant radiographic evidence of lung disease. Three pa-
tients had long standing viremias and two were diagnosed with viral
pathogens in respiratory secretions (Table). On echocardiography 4
of 5 patients had echocardiographic evidence of PH (right ventricu-
lar dysfunction, dilation and/or elevated right ventricular pressure).
One patient was diagnosed with PH on autopsy. Median presenta-
tion of PH after TMA diagnosis was 76d (range 56-101d). Despite
aggressive medical management including inhaled nitric oxide
(iNO) 4 of 5 patients died. One patient recovered from PH after
11 month of sildenafil therapy. Three of the 4 deceased patients
had autopsy done that demonstrated severe pulmonary vasculopathy.
Specifically, lung histology demonstrated severe acute and subacute
TMA as evidenced by endothelial separation in the pulmonary arte-
rioles with fragmented red blood cell extravasation into the intimal
layer and formation of fibrin thrombi. These findings were associ-
ated with marked thickening of all three layers of the vascular wall
with up to 95% occlusion of the arteriolar lumens diagnostic for
PH. Although post-HSCT TMA usually affects renal vessels, it
can also be associated with significant pulmonary vascular injury pre-
senting as hypoxemic respiratory failure with PH following HSCT.
In conclusion, HSCT patients with unexplained hypoxemia and re-
spiratory failure should be evaluated for TMA and PH accordingly.m HSCT (day 0)
TMA/PH Therapy Status Lung Biopsy (B) or Autopsy (A)
132/208 iNO Dead A: Severe TMA and
PE. In situ +CMV
15/71 iNO Dead A: Severe TMA and PE
91/169 iNO Dead A: Severe TMA and PE
17/79 iNO Dead Autopsy not done
149/250 Sildenafil Alive B: Constrictive bronchiolitis,
mild vasculopathy
syndrome; FA: Fanconi anemia; CML: chronic myelogenous leukemia;
d donor; NS: nasal secretions; BAL: bronchoalveolar lavage; CMV: cyto-
chocardiography; path: pathology evaluation; iNO: inhaled nitric oxide.
